Nectar Lifescience Q2 Results 2026: PAT ₹3 Cr (turned profitable)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹0Cr
- −99.8% YoY
- 0% QoQ
- Net profit
- ₹3Cr
- Turned profitable YoY
- Turned profitable QoQ
- Margin
- −66800%
- −66779.2 pp YoY
- +210200 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Nectar Lifescience Ltd Q2 FY27 key numbers
- Revenue
- Reported revenue from operations for the quarter ended 30-Sep-26 (standalone) was Rs. 1.10 lakhs sales and Rs. 0 total volume, compared to Rs. 0 sales and volume for the same quarter in the prior year (30-Sep-25).
As stated in Nectar Lifescience Ltd's Q2 FY27 results statement · published 14 Nov 2026. Reported figures, not investment advice.
Based on Nectar Lifescience Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Reported revenue from operations for the quarter ended 30-Sep-26 (standalone) was Rs. 1.10 lakhs sales and Rs. 0 total volume, compared to Rs. 0 sales and volume for the same quarter in the prior year. Quarterly EBITDA: ₹52.7 crore, down 88% YoY.
From Nectar Lifescience Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Nectar Lifescience's revenue grow in the September 2026 quarter?
- Reported revenue from operations for the quarter ended 30-Sep-26 (standalone) was Rs. 1.10 lakhs sales and Rs. 0 total volume, compared to Rs. 0 sales and volume for the same quarter in the prior year (30-Sep-25).
- Consolidated revenue from operations for the quarter was Rs. 161.03 lakhs, down significantly from Rs. 9,327.02 lakhs for 30-Sep-25, reflecting a large decline primarily due to discontinued operations (capsule business slump sale).
- Total income (including other income) consolidation was Rs. 1,406.81 lakhs for continuing operations for the quarter, up from Rs. 74.07 lakhs in the same period last year on a standalone basis.
2 more points from Nectar Lifescience Ltd's call on revenue
Create a free account to keep reading this call
What happened to Nectar Lifescience's margins in Q2 FY27?
Quarterly EBITDA: ₹52.7 crore, down 88% YoY
Locked: what Nectar Lifescience Ltd said on margins
Also locked on this page: fundraising
Free account, 30 seconds. No card needed.
What capex is Nectar Lifescience planning?
2 more points from Nectar Lifescience Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Nectar Lifescience raising money or cutting debt?
Under Cash Flow from Financing Activities (Annexure 2, Page 12), there is no proceeds from term loans or…
Locked: what Nectar Lifescience Ltd said on fundraising
Also locked on this page: margins
Free account, 30 seconds. No card needed.
How big is Nectar Lifescience's order book?
Nectar Lifescience Ltd — Quarterly revenue & net profit
Nectar Lifescience Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 0 | 5 | -99.8% | 0 | 0% |
| Operating profit (EBITDA) | -7 | -1 | — | -28 | — |
| Operating margin | -66800% | -20.8% | -66779.2 pp | -277000% | +210200 pp |
| Profit before tax | 7 | -1 | — | -25 | — |
| Net profit (PAT) | 3 | -176 | — | -15 | — |
| EPS (₹) | 0.14 | -7.84 | — | -0.79 | — |
Source: Nectar Lifescience Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹0 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Orchid Pharma (Q2 FY27)
4,280.8 lakhs (~14.3% increase). Key results statement takeaways from Orchid Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Gujarat Themis Biosyn (Q2 FY27)
Standalone: ₹4,745.52 Lakhs . Key results statement takeaways from Gujarat Themis Biosyn Ltd's Q2 FY27 results statement — and how it ranks against sector peers
- Gufic BioScience (Q2 FY27)
288.4 crore, up from Rs. Key investor presentation takeaways from Gufic BioSciences Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q2 FY27)
Q2 FY27 Total Income:** ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Key investor presentation takeaways from KRM Ayurv
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nectar Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nectar Lifescience Ltd Q2 FY27 results?
Reported revenue from operations for the quarter ended 30-Sep-26 (standalone) was Rs. 1.10 lakhs sales and Rs. 0 total volume, compared to Rs. 0 sales and volume for the same quarter in the prior year. Quarterly EBITDA: ₹52.7 crore, down 88% YoY.
What is Nectar Lifescience Ltd share price analysis?
Nectar Lifescience Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹205 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Nectar Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.